Alzinova AB (publ) (ALZ.ST)
SEK 1.75
(-7.1%)
SEK 1.75
(-7.1%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 36.39 Million SEK | 22.46% |
| 2022 | 29.71 Million SEK | 19.64% |
| 2021 | 24.84 Million SEK | 16.1% |
| 2020 | 21.39 Million SEK | 64.76% |
| 2019 | 12.98 Million SEK | -4.07% |
| 2018 | 13.53 Million SEK | 77.32% |
| 2017 | 7.63 Million SEK | -2.69% |
| 2016 | 7.84 Million SEK | 130.42% |
| 2015 | 3.4 Million SEK | 390.76% |
| 2014 | 693.78 Thousand SEK | 36.19% |
| 2013 | 509.43 Thousand SEK | -75.23% |
| 2012 | 2.05 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 7.81 Million SEK | -26.92% |
| 2024 Q2 | 4.76 Million SEK | -39.02% |
| 2023 Q2 | 9.92 Million SEK | 10.98% |
| 2023 Q4 | 10.69 Million SEK | 56.64% |
| 2023 Q1 | 8.94 Million SEK | 9.74% |
| 2023 FY | 36.39 Million SEK | 22.46% |
| 2023 Q3 | 6.82 Million SEK | -31.2% |
| 2022 Q4 | 8.15 Million SEK | 35.71% |
| 2022 Q3 | 6 Million SEK | -5.65% |
| 2022 FY | 29.71 Million SEK | 19.64% |
| 2022 Q2 | 6.36 Million SEK | -30.8% |
| 2022 Q1 | 9.19 Million SEK | 77.9% |
| 2021 Q3 | 3.82 Million SEK | -48.55% |
| 2021 FY | 24.84 Million SEK | 16.1% |
| 2021 Q1 | 8.42 Million SEK | 40.58% |
| 2021 Q2 | 7.42 Million SEK | -11.8% |
| 2021 Q4 | 5.17 Million SEK | 35.29% |
| 2020 Q2 | 3.26 Million SEK | -58.55% |
| 2020 FY | 21.39 Million SEK | 64.76% |
| 2020 Q4 | 5.99 Million SEK | 40.43% |
| 2020 Q3 | 4.26 Million SEK | 30.67% |
| 2020 Q1 | 7.87 Million SEK | 57.58% |
| 2019 Q1 | 3.21 Million SEK | 34.56% |
| 2019 Q4 | 4.99 Million SEK | 171.94% |
| 2019 Q2 | 2.93 Million SEK | -8.67% |
| 2019 Q3 | 1.83 Million SEK | -37.39% |
| 2019 FY | 12.98 Million SEK | -4.07% |
| 2018 Q2 | 3.77 Million SEK | -11.15% |
| 2018 Q1 | 4.25 Million SEK | 52.44% |
| 2018 FY | 13.53 Million SEK | 77.32% |
| 2018 Q4 | 2.38 Million SEK | -23.44% |
| 2018 Q3 | 3.11 Million SEK | -17.4% |
| 2017 Q3 | 1.39 Million SEK | -22.63% |
| 2017 Q2 | 1.8 Million SEK | 9.88% |
| 2017 Q1 | 1.64 Million SEK | -38.48% |
| 2017 FY | 7.63 Million SEK | -2.69% |
| 2017 Q4 | 2.78 Million SEK | 99.64% |
| 2016 Q2 | 2.3 Million SEK | 33.65% |
| 2016 Q4 | 2.67 Million SEK | 76.64% |
| 2016 Q1 | 1.72 Million SEK | -38.92% |
| 2016 FY | 7.84 Million SEK | 130.42% |
| 2016 Q3 | 1.51 Million SEK | -34.33% |
| 2015 Q4 | 2.82 Million SEK | 343.39% |
| 2015 Q1 | 362.33 Thousand SEK | 95.6% |
| 2015 FY | 3.4 Million SEK | 390.76% |
| 2015 Q3 | 636.09 Thousand SEK | 9.92% |
| 2015 Q2 | 578.67 Thousand SEK | 59.71% |
| 2014 FY | 693.78 Thousand SEK | 36.19% |
| 2014 Q4 | 185.24 Thousand SEK | 0.0% |
| 2013 FY | 509.43 Thousand SEK | -75.23% |
| 2012 FY | 2.05 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | 5.812% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 88.68% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 89.823% |
| Xintela AB (publ) | 57.31 Million SEK | 36.499% |
| Active Biotech AB (publ) | 44.8 Million SEK | 18.775% |
| Amniotics AB (publ) | 29.07 Million SEK | -25.193% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -148.386% |
| BioArctic AB (publ) | 89.62 Million SEK | 59.392% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 97.596% |
| Camurus AB (publ) | 1.05 Billion SEK | 96.565% |
| Cantargia AB (publ) | 290.01 Million SEK | 87.45% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -66.23% |
| CombiGene AB (publ) | 44.14 Million SEK | 17.552% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 74.546% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -28.488% |
| Genovis AB (publ.) | 88.19 Million SEK | 58.733% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 68.371% |
| Mendus AB (publ) | 129.13 Million SEK | 71.816% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -400.771% |
| Intervacc AB (publ) | 79.78 Million SEK | 54.382% |
| Kancera AB (publ) | 63.07 Million SEK | 42.299% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -559.467% |
| LIDDS AB (publ) | 27.75 Million SEK | -31.147% |
| Lipum AB (publ) | 37.3 Million SEK | 2.442% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -401.737% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 73.221% |
| NextCell Pharma AB | -576.01 Thousand SEK | 6418.542% |
| OncoZenge AB (publ) | 15.9 Million SEK | -128.834% |
| Saniona AB (publ) | 1.07 Million SEK | -3279.387% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 79.973% |
| Ziccum AB (publ) | 27.87 Million SEK | -30.555% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -121.913% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 88.148% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 14.628% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -105.825% |
| Corline Biomedical AB | 30.16 Million SEK | -20.644% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 37.282% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 56.239% |
| Aptahem AB (publ) | 10.01 Million SEK | -263.489% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 72.979% |
| Fluicell AB (publ) | 28.61 Million SEK | -27.183% |
| Biovica International AB (publ) | 133.72 Million SEK | 72.782% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -83.911% |
| AcouSort AB (publ) | 25.87 Million SEK | -40.655% |
| Abliva AB (publ) | 27.86 Million SEK | -30.611% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 81.191% |
| 2cureX AB (publ) | 36.51 Million SEK | 0.334% |
| I-Tech AB | 40.14 Million SEK | 9.345% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 95.765% |
| Cyxone AB (publ) | 28.21 Million SEK | -29.0% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 66.722% |
| Biosergen AB | 26.8 Million SEK | -35.76% |
| Nanologica AB (publ) | 69.88 Million SEK | 47.922% |
| SynAct Pharma AB | 224.49 Million SEK | 83.788% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 17.611% |
| BioInvent International AB (publ) | 441.4 Million SEK | 91.754% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -51.94% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 87.439% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -363.273% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 67.185% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -147.592% |